Russell Schundler Sells 2,576 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA - Get Free Report) General Counsel Russell Schundler sold 2,576 shares of Liquidia stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $28,619.36. Following the sale, the general counsel now owns 486,048 shares of the company's stock, valued at approximately $5,399,993.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Russell Schundler also recently made the following trade(s):

• On Tuesday, September 3rd, Russell Schundler sold 710 shares of Liquidia stock. The shares were sold at an average price of $9.50, for a total value of $6,745.00.

Liquidia Trading Up 2.2 %

Shares of LQDA stock traded up $0.25 on Tuesday, hitting $11.38. 772,491 shares of the stock were exchanged, compared to its average volume of 1,004,987. The business has a 50-day moving average of $10.40 and a 200 day moving average of $12.00. Liquidia Co. has a fifty-two week low of $5.71 and a fifty-two week high of $16.99. The firm has a market capitalization of $869.59 million, a P/E ratio of -7.20 and a beta of 0.22.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. The firm had revenue of $3.66 million for the quarter, compared to analyst estimates of $7.92 million. As a group, research analysts forecast that Liquidia Co. will post -1.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on LQDA shares. Lifesci Capital started coverage on Liquidia in a report on Thursday, October 3rd. They issued an "outperform" rating and a $30.00 price objective for the company. Oppenheimer assumed coverage on Liquidia in a research note on Tuesday, June 25th. They issued a "market perform" rating for the company. HC Wainwright reduced their price objective on shares of Liquidia from $32.00 to $29.00 and set a "buy" rating on the stock in a research note on Tuesday, August 20th. BTIG Research lowered their target price on shares of Liquidia from $29.00 to $25.00 and set a "buy" rating for the company in a research note on Monday, August 19th. Finally, Bank of America cut their target price on shares of Liquidia from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Liquidia currently has an average rating of "Moderate Buy" and an average target price of $24.00.

Institutional Investors Weigh In On Liquidia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC bought a new stake in Liquidia during the second quarter worth $27,000. Hilltop National Bank bought a new stake in shares of Liquidia in the 2nd quarter valued at about $33,000. Whitcomb & Hess Inc. lifted its stake in Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company's stock valued at $116,000 after purchasing an additional 1,074 shares during the last quarter. Deuterium Capital Management LLC bought a new position in Liquidia during the second quarter worth about $120,000. Finally, DMC Group LLC bought a new position in Liquidia during the second quarter worth about $122,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.